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Abstract
Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes show promise for screening
during early drug development. Here, we tested a hypothesis that in vitro assessment of multiple
cardiomyocyte physiological parameters enables predictive and mechanistically-interpretable
evaluation of cardiotoxicity in a high-throughput format. Human iPSC-derived cardiomyocytes
were exposed for 30 minutes or 24 hours to 131 drugs, positive (107) and negative (24) for in vivo
cardiotoxicity, in up to 6 concentrations (3 nM to 30 μM) in 384-well plates. Fast kinetic imaging
was used to monitor changes in cardiomyocyte function using intracellular Ca2+ flux readouts
synchronous with beating, and cell viability. A number of physiological parameters of
cardiomyocyte beating, such as beat rate, peak shape (amplitude, width, raise, decay, etc.) and
regularity were collected using automated data analysis. Concentration-response profiles were
evaluated using logistic modeling to derive a benchmark concentration (BMC) point-of-departure
value, based on one standard deviation departure from the estimated baseline in vehicle (0.3%
dimethylsulfoxide)-treated cells. BMC values were used for cardiotoxicity classification and
ranking of compounds. Beat rate and several peak shape parameters were found to be good
predictors, while cell viability had poor classification accuracy. In addition, we applied the
Toxicological Prioritization Index approach to integrate and display data across many collected
parameters, to derive “cardiosafety” ranking of tested compounds. Multi-parameter screening of
beating profiles allows for cardiotoxicity risk assessment and identification of specific patterns
defining mechanism-specific effects. The data and analysis methods may be used widely for
compound screening and early safety evaluation in the drug development process.
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Introduction
Cardiotoxicity is a well-known side effect of many drugs and a leading cause of safety-
based compound attrition in preclinical drug development (Kola and Landis, 2004; Laverty
et al., 2011). Sensitive in vitro assays that can provide early detection of cardiovascular side
effects have been the focus of toxicology research for several decades (Lawrence et al.,
2008). Specifically, new cell models that better represent the in vivo environment, as well as
new phenotypic readouts that are related to myocardial performance, are needed to develop
a sensitive, specific, and predictive assay. Equally important is a requirement for assays to
be amenable to high-throughput screening in a self-regenerating cell-based model. Thus,
while primary cardiomyocytes or myocardial tissue preparations have been used, stem cell-
derived cardiomyocytes have become a popular model (Anson et al., 2011; Mercola et al.,
2013; Scott et al., 2013). Human induced pluripotent stem cell (iPSC)-derived
cardiomyocytes, an infinitely expandable source of cells from multiple individuals, are
especially attractive, as they recapitulate the expected genetic, genomic, biochemical,
mechanical, and electrophysiological behaviors of human cardiomyocytes and heart tissue
(Guo et al., 2011; Cerignoli et al., 2012; Rana et al., 2012; Puppala et al., 2013; Sirenko et
al., 2013).
Synchronous spontaneous rhythmic beating is a phenotype employed by most in vitro
approaches for evaluating the cardiac-specific function. A wide array of methods is utilized
in iPSC-based screening [reviewed in (Scott et al., 2013)], such as automated patch clamp,
microelectrode arrays, mechanical movement, Ca2+ transients, and cellular impedence.
Although the diversity of the detection methods creates an opportunity to screen specific
phases of the contractile cascade, scalability of these assays to the high-throughput setting
has not been addressed, as typically several dozen or fewer compounds are considered, and
only over a limited range of concentration. One example of a successful integration of in
vitro assays into a cardiotoxicity testing pipeline is the human Ether-a-go-go Related-Gene
(hERG) potassium channel, a well-established molecular target for arrhythmia-causing
drugs. High-throughput screening using recombinant hERG ion channels and radiolabelled
ligands, combined with structure-activity modeling for hERG selectivity of drug candidates,
is now used routinely in drug safety testing (Taboureau and Jorgensen, 2011).
Our previous study showed that iPSC-derived cardiomyocytes are amenable to automated
assays for measuring the impact of drugs on the beating rate, mechanical activity, and
intracellular calcium handling (Sirenko et al., 2013). By utilizing fast kinetic fluorescence
imaging of intracellular Ca2+ levels, together with automated signal analysis software, we
demonstrated that the phenotypic response of spontaneously contracting cardiomyocytes
may be characterized with a variety of parameters indicative of the cardiac physiology. We
reasoned that this assay, coupled with robotic liquid handling, is well-suited for quantitative
high-throughput screening (HTS) and demonstrate the potential of this approach for
investigative toxicology applications. Specifically, we tested a hypothesis that in vitro
assessment of multiple cardiomyocyte physiological beating parameters enables predictive
and mechanistically-interpretable evaluation of cardiotoxicity in a high-throughput format.
We used a library of 131 compounds representing different groups of cardiotoxic and
cardiosafe drugs to enable characterization of the classification accuracy of the assay. In
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addition we have proposed and validated methods for statistical analysis and ranking of
compounds for cardiac safety.
Methods
Chemicals
A library of pharmacologically active compounds (Screen-Well Cardiotoxicity Library,
BML-2850, ENZO Life Sciences, Farmingdale, NY) was used in these studies. The library
(see Supplemental Table 1 for the list) contains 131 compounds representing blockers of
Na+, K+ and Ca2+ channels, hERG blockers, adreno receptor agonists and antagonists,
dopamine receptor antagonists, histamine receptor antagonists, anti-inflammatory and anti-
viral drugs with known cardiac side effects. The library also includes a number of anti-
cancer drugs, representing anthracyclines, kinase inhibitors, and receptor antagonists. In
addition, there were 24 chemicals classified as non-toxic by the manufacturer. All
compounds were prepared as 10 mM stock in 100% dimethyl sulfoxide (DMSO).
Human iPSC-derived cardiomyocytes and cell culture
Human iPSC-derived cardiomyocytes (iCell™ Cardiomyocytes), plating medium, and
maintenance medium were obtained from Cellular Dynamics International (Madison, WI).
Differentiation protocols and cell culture conditions were as detailed previously in Ma et al.
(Ma et al., 2011) and Sirenko et al. (Sirenko et al., 2013) Cells were plated into gelatin
coated wells at 8,000 cells/well in 384 multi-well plates. Strong synchronous contractions of
cells were evident after 7 days of culture. Experiments were conducted 8–10 days post-
plating on plates where all wells demonstrated regular synchronous contractions [on average
25 beats/minute, see Figure 2 and (Sirenko et al., 2013)]. Compound plates were pre-
warmed to 37°C before chemicals were added to cells. Concentration of DMSO was 0.1% in
chemical and vehicle-only containing wells (except for 30 μM wells where it was 0.3%). In
30 min exposure experiments, FLIPR® Calcium Assay Kit 5 (Molecular Devices) reagents
were added to each well and cells incubated for 30 minutes. Then, chemicals (in duplicates)
or DMSO alone (30–38 wells/plate) were added to wells and cells were incubated for
additional 30 min. For 24 hr exposure experiments, cells were incubated with chemicals for
23.5 hrs, FLIPR® Calcium Assay Kit 5 or cell viability (see below) reagents added, and data
acquired 30 min thereafter. All experiments were performed at 37°C and 5% CO2. Data
acquisition on FLIPR system was performed at 37°C.
Imaging was used in parallel to assess cell viability. To determine viability, cells were
incubated for 30 min with a mixture of three dyes: 2 μM Calcein AM, 2 μg/ml Hoechst
33258, and 200 nM of MitoTracker Orange (all from Invitrogen, Carlsbad CA). Images
were acquired using ImageXpress® Micro XL automated microscope (Molecular Devices,
Sunnyvale, CA) using a 10x objective (NA = 0.3). The light source was a solid state white
light engine with emission from 380 nm to 680 nm. A FITC filter cube (Ex 482/35, Em
536/40) (center wavelength(nm)/bandpass width(nm)) was used for Calcein AM. A TRITC
filter cube (Ex. 543/22, Em 593/40) was used for MitoTracker Orange. A DAPI filter cube
(Ex 377/50, Em 447/60) was used for Hoechst nuclear stain. Output parameters included
total cell number, number of viable cells, and number of cells with intact mitochondria. As
initial analysis showed high correlation between cell viability and mitochondria integrity
(data not shown), we used only cell viability scoring (number of viable, i.e. Calcein AM-
positive cells in each well) for further analysis.
Data collection
The FLIPR® Tetra high-throughput cellular screening system combined with a
TetraCycler™ Microplate Handler (Molecular Devices) was used in these experiments.
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Fluorescence of FLIPR Calcium 5 dye (Ex. 485nm, Em. 530nm) was acquired at 8 frames
per second (fps), and up to 800 image frames were collected while cells were maintained at
37°C. The total time for image acquisition and analysis was approximately 2 min per plate.
An automated algorithm in ScreenWorks® Peak Pro™ software (Molecular Devices) was
used to process the data. Description of peak detection and fitting of a binomial function to
calculate multivariate parameters are included in Sirenko et al. (Sirenko et al., 2013) Briefly,
beat rate, peak amplitude, peak width (at 10% amplitude), peak spacing, peak rise (time
from 10% to 90%), peak decay (time from 90% to 10%), and peak irregularity were derived.
Cell viability was assessed as a number of viable (Calcein AM positive) cells per field. Raw
data, as well as data normalized to plate-specific vehicle (DMSO)-containing wells, for each
endpoint are available as Supplemental Tables 2 and 3.
Concentration-response curve fitting, derivation of benchmark concentrations and ranking
of compounds
Normalized data for each chemical and endpoint were used to fit a concentration-response
quantitative logistic function and to visualize the concentration-response relationship, using
the R software version 2.15.2 (see Supplemental Methods for script). Variability of the
DMSO-only wells was used to derive the benchmark concentration (BMC) (EPA, 2012),
which involves modeling to obtain dose levels corresponding to specific response levels
near the low end of the observable range of the data. An accepted approach for continuous
data is to define a point-of-departure (i.e., benchmark) response as a change in the mean
equal to one control standard deviation from the control mean, and thus we tested various
cut-offs from 0.25 to 3 standard deviations at 0.25 intervals.
For comparing receiver operating characteristic (ROC curves) of classification accuracy of
BMCs obtained at different points-of-departure we used visualization and partial area under
the curve (AUC) calculations with the pROC R package (Robin et al., 2011). Receiver
operating characteristic plots were created to illustrate the performance of a binary classifier
(cardiotoxic vs. safe) by plotting the fraction of true positives out of the positives vs. the
fraction of false positives out of the negatives at various threshold settings. The area under
the curve of the ROC plot is then used as common metric to assess the classification
accuracy of a classifier (Fawcett, 2006). The AUC derived from the ROC curves are equal to
the probability that a classifier will rank a randomly chosen positive instance higher than a
randomly chosen negative one.
An interactive Toxicological Prioritization Index (ToxPi™) application (Reif et al., 2013)
was used to integrate evidence across endpoints and to visualize the relative prioritized ranks
of compounds.
Chemical descriptors
Two-dimensional chemical descriptors were calculated with Dragon software (v.5.5, Talete
SRL, Milan, Italy). Descriptors were not calculated for two inorganic compounds (arsenic
trioxide, cisplatin [cis-diamineplatinum(II)dichloride]) and two organometallic compounds
(bortezomib, sodium stibogluconate). After removing descriptors with low variance
(SD<10−6) and highly correlated descriptors (if pairwise r2>1.0, one of the pair was
randomly removed), descriptors were range-scaled to the [0,1] interval.
Results
High-throughput cardiomyocyte beating assay
We developed methods for measuring the impact of drug candidates on the beating rate of
human iPSC derived cardiomyocytes using fast kinetic fluorescence imaging.
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Cardiomyocyte contraction rate and pattern are characterized by monitoring changes in
intracellular Ca2+ measured using calcium sensitive dyes. The assay allows characterization
of beating profiles by using multi-parameter analysis outputs such as beating rate, peak
frequency and width, or waveform irregularities. (Sirenko et al., 2013). One of the major
objectives of this study was to determine the feasibility of conducting the cardiomyocyte
beating assay that employs fluorescent dyes to monitor changes in Ca2+ transients in a high-
throughput format. Intracellular calcium ion fluxes are an integral part of the cardiomyocyte
contraction process (Bers, 2002). Because Ca2+ transients are synchronous with cell beating
(Qian and Guo, 2010; Sirenko et al., 2013), simultaneous monitoring of the beat rate,
amplitude, and a multitude of other parameters affords evaluation of the physiological
function of the heart (i.e., contractility) in vitro. Concordance between mechanical
contraction and modulation of Ca2+ signal was demonstrated previously (Sirenko et al.,
2013). The cells were cultured in a near-confluent monolayer and the average fluorescence
intensity of all cells in a well was recorded over time. Typical images of cells going through
a contraction cycle were observed [Supplemental Figure 1, see Sirenko et al. (Sirenko et al.,
2013)]. The assay was optimized for a 384-well format to make it suitable for screening
compound libraries. The assay variability was assessed for different output parameters on an
inter- and intra-plate basis. Well-to-well coefficients of variation were 15% or less for most
parameters, with the exception of peak amplitude. Visualization of the effects of chemicals
on individual beating pattern parameters is shown in Figure 1. Overall concentration-
response and compound similarities are evident from the heat map and hierarchical
clustering for most of the compounds from the screened library identified as cardiotoxic
(Figure 1, top), while little effect was observed with non-toxic compounds (Figure 1,
bottom). When all screened compounds were combined and hierarchical clustering was
performed, non-toxic compounds clustered (not shown) with some of the cardiotoxic agents
that were without effect in this experiment (see below for a more detailed analysis of the
classification accuracy and concentration-response analysis).
Even based on a very general clustering analysis we observed that known classes of
cardiotoxic compounds had expected effects. For example, cardiac glycosides (e.g., digoxin
and digitoxin) blocked beating completely at 3 μM. Antiarrythmic compounds (Na+ channel
blockers lidocaine, disopyramide, flecainid acetate, and quinidine) had little effect on the
beating rate, but affected spacing between peaks and regularity. Non-selective and selective
α- and β-adrenergic receptor blockers (amiodarone, soltalol, pindolol) had negative
chronotrope effect, while isoproterenol (β-agonist) had positive chronotrope effect. Ca2+
channel blockers (bepridil, verapamil, diltiazem, and nicardipine) and anti-histamine
compounds with known hERG blocker hazard (astemizol and terfenadine) strongly inhibited
beat rate. At the same time, it should be noted that some compounds had hormesis-like
concentration effects: beating rate increased at low concentrations, but decreased or
completely stopped at high doses (e.g., digoxin, salmeterol). This pattern is consistent with
positive chronotrope effects at low concentrations and toxic effects at higher concentrations.
A number of cardiotoxic compounds in this library did not have an effect at 30 minutes.
Included in this group were several anti-inflammatory drugs (ibuprofen, meloxicam,
indomethacin, diclofenac and rofecoxib), anti-diabetic drugs (rosiglitazone, pioglitazone)
and most anti-cancer drugs that inhibit cell proliferation or cause apoptosis (doxorubicin,
daunorubicin, cisplatin, 5-fluoracil).
As it is expected that different drugs may vary in the timing of their effects on
cardiomyocytes (e.g., channel blockers/receptor antagonists vs. anti-cancer drugs), we used
two time-points, 30 min and 24 hrs, to account for both types of toxicity. Separate plates
were used for each time point. Importantly, beating rate and other parameters exhibited
considerable concordance among 30 min and 24 hrs time-points, both without treatment and
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upon exposure to compounds (Figure 1). Most compounds exhibited adverse effects at the
same compound concentrations at either 30 min, or 24 hrs. It should be noted, however, that
cardiomyocyte beating is sensitive to media temperature and that these experiments should
be performed under tight environmental control (data not shown).
Analysis of the concentration response
We tested the library of compounds in a 384-well plate format, in duplicates, using 6 and 4
concentrations for 30 min and 24 hrs exposure, respectively (see Figure 1, or Supplemental
Tables 2 and 3). We also found that up to 0.3% DMSO does not have an effect on the
assessed parameters as compared to media-only wells (data not shown). Thus, we used 30–
38 wells/plate to estimate the variance in negative control data (i.e., vehicle-only treated
cells).
The effective concentration at 50% of the maximum response (EC50) is the reference point
that is used most frequently in the analysis of in vitro data; however, the use of the EC50
may be problematic in cases when 50% response is far outside the range of concentrations
tested. In addition, it is expected that not every tested chemical will elicit the “maximum
effect” (for example a non-toxic compound), which complicates the process of fitting the
Hill function or the equivalent parameter in other sigmoidal models. Because the vehicle-
only effect level was normalized across plates, we performed four-parameter maximum-
likelihood logistic modeling to fit the experimental data at test concentrations using
duplicate measurements (see Figure 2 for a representative concentration-response analysis).
In accordance with the US EPA guidance for dose-response modeling (EPA, 2012) and
determination of the point-of-departure value, we selected a one standard deviation
departure from the control mean as the benchmark response from which a BMC was derived
(see Figure 2, top right panel). If the maximum response did not reach this level in the
concentration range tested, the “no observable adverse effect level” was recorded as 30 μM,
the highest concentration used. Identical curve fitting and BMC derivation procedures were
applied to all chemicals and phenotypes collected (except for peak irregularity which is a
binary parameter). For example, while disopyramide had no effect on the beat rate at the 30
min exposure time-point, it had a clear concentration-dependent effect on the peak shape
parameters (Figure 2). No effect on cell viability, evaluated 24 hrs after treatment, was
observed for disopyramide.
Classification of cardiotoxicity based on multiparametric phenotyping using iPSC-derived
cardiomyocytes
While the shape and frequency of Ca2+ transient peaks, as well as the information on cell
viability, provide an opportunity to evaluate specific mechanisms of cardiotoxicity, a more
global ranking of the potential hazard is also of potential value for decision-making in drug
and chemical safety evaluation. First, we compared the effects of cardiotoxic vs non-toxic
chemicals for each phenotype (Figure 3). BMCs for the beat rate and peak shape parameters
were found to be significantly different between groups, while there was no difference in
cell viability.
Second, we aimed to determine the classification accuracy (cardiotoxic vs non-toxic) of the
BMC values in each parameter (Figure 4). We found that the highest classification accuracy,
for the compound library that was tested, was achieved with the beat rate phenotype, with
the receiver operating characteristic plot of sensitivity vs. specificity AUC of 0.8 and 0.91
for 30 min and 24 hrs time-points, respectively. Cell viability and peak rise time were poor
classifiers. To evaluate whether an alternate choice for the point-of-departure cutoff would
affect classification accuracy, we derived BMCs at different fractions of standard deviation
of the mean for vehicle-treated cells, from 0.25 to 3 in 0.25 increments. This analysis
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showed that a choice of one standard deviation generates consistently high classification
accuracy among all phenotypes (Supplemental Table 4).
Third, because strong structure-activity relationships have been established between inherent
chemical properties and certain types of cardiotoxicity (Frid and Matthews, 2010), we
conducted principal component analysis of cardiotoxic vs. non-toxic compounds in the
tested library based on the chemical descriptors (Figure 5A). From the plot of the first two
principal components it is evident that non-toxic compounds were largely representative of
the chemical space of the entire chemical library. In addition, we used principal component
analysis to visualize the distribution of cardiotoxic and non-toxic compounds using
multiparametric assessment of iPSC-derived cardiomyocyte beating patterns (Figures 5B
and C). Clearly, non-toxic compounds showed response profiles that were more similar to
each other than to most cardiotoxic compounds at either time point. Most of the signal in
principal component 1 for the 30 min time-point (Figure 5B) was contributed by drugs that
had dopamine- and/or histamine-ergic properties (triangles); while principal component 2
was largely separating ion (Na+, K+, or Ca2+) channel blockers from other compounds
(diamonds).
Ranking of compounds for cardiotoxicity potential
We have shown previously that significant correlation exists between the effect levels
derived from the in vitro analysis of cardiac beating parameters and both Cmax and results
of other assays for cardiotoxicity (Sirenko et al., 2013). While comparisons of in vitro-
derived effect levels to Cmax has been suggested as a surrogate metric for ranking
compounds with respect to their potential in vivo cardiotoxicity potential (Guo et al., 2011),
this approach is not amenable to drugs or chemicals that lack necessary pharmacokinetic
studies (i.e., compounds early in development). Thus, we considered an alternative approach
to integrating multiple parameters collected in this study to rank chemicals in the screened
library for their overall cardiotoxicity and cytotoxicity hazard (Figure 6). Each compound’s
BMC values for the effects on beat rate, peak shape (spacing, amplitude, rise, decay and
width), and cell viability were analyzed and visualized using the ToxPi approach (Reif et al.,
2013), which generates transparent graphical rankings to facilitate decision making (see
Supplemental Tables 5 and 6 for ToxPi input data files). The analysis of the data for both 30
min (Figure 6A) and 24 hrs (Figure 6B) time points showed that non-toxic compounds were
ranked high for safety, while most cardiotoxic compounds were ranked low. Significant
correlation of ToxPi values was observed between 30 min and 24 hr time points
(rPearson=0.65, rSpearman=0.62).
Discussion
This work was aimed at addressing several major barriers that preclude wide use of human
iPSC-derived cardiomyocytes as an in vitro model for cardiotoxicity screening, such as (i)
throughput, (ii) data integration across multiple parameters, and (iii) quantitative assessment
of the concentration-response. Despite some limitations of iPSC-derived cardiomyocytes
(Scott et al., 2013) (e.g., neonatal phenotype, mixed culture of various cardiomyocyte
subtypes, un-physiological two-dimensional alignment of cells in culture, etc.), their use
represents a future of cardiotoxicity testing. A virtually unlimited supply of functionally
competent cells (i.e., spontaneously and synchronously contracting), and a promise to create
cells from multiple individuals, including patients with cardiovascular diseases (Liang et al.,
2013), make this model system invaluable not only for biomedical research, but also for
safety screening of drugs and environmental chemicals.
First advantage of our model system is throughput. The throughput of the technologies that
have been reported to date (Qian and Guo, 2010; Guo et al., 2011; Ma et al., 2011; Rana et
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al., 2012; Liang et al., 2013; Pointon et al., 2013) is limited to few or as many as several
dozen compounds, and it is not yet clear how the results of the in vitro assays can be used to
predict in vivo toxicity (Guo et al., 2011), or to determine additional tests that may be
needed. In this study, the cardiac beating assay (Sirenko et al., 2013) was optimized for a
384-well format and the results presented herein show that it is a very promising and robust
in vitro phenotyping approach for cardiotoxicity screening in high-throughput format.
Second advantage is the availability of multiple parameters that describe various aspects of
impairment in cardiomyocyte physiology. Each output (beat rate, peak characteristics and
cell viability) generated as a result of multi-parametric data analysis of the beating patterns
of human iPSC-derived cardiomyocytes has tremendous value for understanding the type of
pathophysiological effect that a chemical may have on the heart. For example, we observed
that a number of cardiotoxic compounds known to prolong the QT interval have a profound
impact on the shape of the peaks. Mechanism-based evaluation of clinically-relevant
phenotypes (e.g., association of a polymorphic ventricular tachycardia, so called torsades de
pointes, that can degenerate into ventricular fibrillation and sudden death, with long QT
syndrome) with in vitro screening methods is a promising avenue for triaging drug
candidates early in development. Specifically, this effect was observed for Class Ia
(disopyramide, procainamide, quinidine) and Class III (amiodarone, sotalol) antiarrhythmic
drugs. Other drugs with a similar effect included the commonly used psychotropic
medications imipramine and desipramine and the tricyclic antidepressants (TCA), and these
medications have been associated with cardiac arrhythmias (Alvarez and Pahissa, 2010).
Similarly, this data can distinguish between Na+ channel blockers and hERG blockers. Na+
channel blockers cause increased spacing between peaks (narrow peaks) as well as
irregularities of beating patterns. To the contrary, atypical antipsychotics known to act as
hERG blockers (Alvarez and Pahissa, 2010) have a profile including dramatic increases of
peak width and decay time (wide peaks). The similarity of beating profiles among drugs can
potentially provide clues about the mechanisms for toxicity. For example, bupivacaine, a
Na+ blocker, exhibited a profile different from other Na+ blockers, including the appearance
of wide peaks. Such a phenotype is consistent with K+ blocking and, in fact, bupivacaine has
been shown to have such an effect in the literature (Arias et al., 2007). As another example,
the anti-inflammatory drug dichlophenac had a very similar profile to Na+ channel blockers
and, in fact, Na+ blocking is a known side effect for this compound (Gwanyanya et al.,
2012).
It is also important to point out that the multi-parametric toxicity assessment approach offers
an opportunity to distinguish between general (e.g., loss of cell viability) and organ-specific
effects. While Ca2+ transients will diminish with the loss of cell viability, an effect observed
for many compounds at high enough concentration, detailed concentration-response analysis
(see below) and the ability to weigh different effects (e.g., through ToxPi visualization)
enables the differential analysis. This is supported by our observation that beat rate and
several peak shape parameters were found to be good predictors of cardiotoxicity, while cell
viability had poor classification accuracy. These conclusions should be interpreted with
caution, however, as our experiments did not test repeated, or longer than 24 hrs exposures.
The third advantage of our approach is in its ability to classify chemicals for potential
cardiotoxicity based on quantitative concentration response of multiple parameters.
Quantitative assessment of the potential hazard is critical for understanding the safety
margins of drugs and chemicals, as well as for the informed decisions on the relative ranking
of various drug candidates in development. The most common metric reported from in vitro
studies with a concentration-response design to describe the relationship between
concentration and effect is EC50 (Neubig et al., 2003). While this metric is applicable to
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radiolabeled ligand-receptor interaction, functional in vitro studies may be conducted at
limited ranges of concentrations to avoid non-specific cytotoxicity. The limitations of the
EC50 approach in the analysis of in vitro screening data have been recently addressed by
Sand et al. (Sand et al., 2012). In addition, an accepted approach to estimating the point-of-
departure from continuous data for the purpose of human health assessments conducted by
the US EPA is the benchmark concentration approach where the benchmark response is
defined as one standard deviation of the mean of the control group (EPA, 2012). Because
high-throughput in vitro studies usually include many vehicle control wells and few
experimental replicates, we propose the use of logistic curve modeling to fit the
concentration-response relationships that may not reach the maximum effect, or where it is
not known what the maximum effect is due to absence of assay-specific positive controls.
Indeed, not only were the BMCs derived using this approach highly predictive of
cardiotoxicity hazard (as evident from the AUCs of ROC curves), but our analysis of the
alternative point-of-departure cutoffs, up to 3 standard deviations of the mean of controls,
demonstrated eroding accuracy of classification.
In high-throughput screening, where multiple phenotypes are derived on many chemicals,
the challenge exists to not only compare individual chemicals for each phenotype, but also
across various parameters. For this purpose, we reason that the BMC provides a solid basis
for standardized comparison among compounds within each phenotype. As some of these
phenotypes (e.g., beat rate, peak width) are indicative of particular sub-types of in vivo
manifestations of cardiotoxicity, the availability of a value (i.e., BMC) based on best
practices in risk assessment should facilitate decisions on the potential for the individual
chemicals to cause mechanism-specific toxicity. Still, there are many potential decision-
making scenarios where a more comprehensive metric is needed to provide a global ranking
of compounds for additional in vitro screening in mechanism-based assays or in vivo studies.
The ultimate impact of pharmacological toxicity is dependent upon the projected therapeutic
margin of safety as well as the risk-to-benefit ratio for new drug entities (Williams, 1990).
However, most drugs in development lack pharmacokinetic information necessary to derive
a numeric score for estimating the margin of safety. This is similar to the need for assessing
the relative risks of environmental chemicals based solely on the data from in vitro assays
together with other information such as physico-chemical properties of compounds (Rusyn
et al., 2012), exposure estimates, etc. This challenge can be addressed by integrating
information across different data domains using ToxPi (Reif et al., 2013), which not only
creates a relative rank for the tested compounds, but also provides a comprehensive and
transparent visualization of the resultant rankings. Additional data, such as information from
other assays, estimates of pharmacokinetic parameters, etc. can be easily incorporated so
that diverse sets of chemicals (in environmental screening contexts) or drug candidates from
the same development pipeline can be compared based on the diverse evidence (e.g., data)
and prioritization needs.
It should be noted that our approach and interpretation of the results are not without
limitations. There are several overarching challenges in the use of iPSC-derived
cardiomyocytes as an in vitro model for cardiotoxicity screening [reviewed by Scott et al.
(Scott et al., 2013)]. One of the impediments is the inability to induce differentiation to a
fully mature cardiomyocyte. iPSC cells continue to mature slowly in culture and thus long-
term cultures may vary from batch to batch.
Additional caveats that are more specific to high-throughput screening are also worth noting.
First, cardiotoxicity as an adverse phenotype is a broad term and the commercial library
screened in this study represents compounds with different types of cardiovascular toxicity
and/or adverse events. In addition, some of the cardiotoxicity events are acute, some are
chronic, and some occur as a consequence of toxicity at other organs. Therefore, despite the
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fact that multiple parameters are being collected in the assay detailed herein, the results
should be interpreted with caution and additional phenotypic anchors may need to be
collected to improve specificity of the prediction and offer detailed mechanistic
understanding for each compound of interest. Nonetheless, we posit that our method shows
promise as it allows for rapid and high-throughput screening for both general cytotoxicity
and specific cardiomyocyte beating parameters in concentration-response fashion and yields
informative ranking and prioritization for additional follow-up studies.
Second, the classification results and interpretation of the predictive value of the individual
or combined parameters collected in this assay depend on the assignments of chemicals in
the screened library to classes performed by the commercial vendor supplying the library.
Indeed, alternative assignments could be made for a number of compounds based on the vast
available literature. This limitation may be addressed by additional experiments where
mechanism-specific and organ-specific libraries are screened. While detailed assay
validation was beyond the scope of this work, we note that as our assignment of compounds
to classes was not biased, and that our classification approach which includes collection of
multiple parameters and derivation of BMCs should apply to future testing of a greater
number of, or alternatively-defined chemicals. Likewise, the use of ToxPi for integration of
diverse information across data domains can be utilized for alternative context-dependent
decisions.
Third, while we posit that a quantitative approach that explores concentration-response
findings in this in vitro system is an advantage which enables decisions that go beyond
hazard classification, the challenge of “clinical relevance” is a very important consideration.
Careful comparisons of the “effective dose” observed in this assay and a known or estimated
blood or tissue concentration of the chemical or drug of interest are needed.
Finally, while the assay was scaled up to a 384-well plate format to facilitates screening of
up to 150 compounds per plate, additional experiments are necessary to establish ultra-high
throughput approaches, such as 1536-well plates, for a greater number of compounds and
concentrations.
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• Induced pluripotent stem cell-derived cardiomyocytes are promising in vitro
models
• We tested if evaluation of cardiotoxicity is possible in a high-throughput format
• The assay shows benefits of automated data integration across multiple
parameters
• Quantitative assessment of concentration-response is possible using iPSC cells
• Multi-parametric screening allows for cardiotoxicity risk assessment
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Concentration-dependent effects of screened compounds on peak width and beat rate of
human iPSC-derived cardiomyocytes were visualized using hierarchical clustering and
heatmaps. Colors represent changes in each parameter (see color scale bars). Values from
duplicate plates were averaged to generate the heatmap. Compounds classified as
cardiotoxic in Screen-Well™ Cardiotoxicity Library (107 chemicals) were clustered
separately (top part of the figure) from those classified as non-toxic (24, bottom part of the
figure). The complete list of compounds (131) used in this study is available as
Supplemental Table 1.
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Quantitative analysis of human iPSC-derived cardiomyocyte beating patterns (top left) was
conducted using four-parameter logistic curve fits to the data. Before plotting, individual
response values were normalized to plate-specific vehicle (DMSO) control values of each
parameter. A benchmark response for the point-of-departure benchmark concentration in the
concentration-response curve (vertical dashed lines) was defined as a one standard deviation
departure from the mean for vehicle control wells (horizontal dashed lines).
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Distributions of BMC values for non-toxic (white) and cardiotoxic (grey) compounds were
plotted using box-and-whiskers plots (line - mean, box - inter-quartile range, whiskers - 5
and 95%, outliers – dots) for each parameter separately at 30 min (A) and 24 hr (B) time
points. Differences in the means of BMCs between non-toxic and cardiotoxic compounds
for each parameter were compared using t-tests and the level of significance is displayed
with asterisks (*, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; n.s., p>0.05).
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Receiver Operating Characteristics curves that display the relationship between sensitivity
and specificity were obtained from the analysis of the classification accuracy (cardiotoxic vs
non-toxic labels of compounds in Screen-Well™ Cardiotoxicity Library) using BMC values
(left – 30 min time point; right – 24 hr time point) for each of the parameters shown. AUC
values for each ROC curve is displayed.
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Principal component analysis (first two principal components shown with percent global
variability explained indicated in parentheses) of chemical similarity vs. multi-parametric
assessment of cardiotoxicity. A, Chemical diversity of Screen-Well™ Cardiotoxicity Library
drugs using Dragon descriptors. B, Responses at each concentration for beat rate and peak
shape (spacing, amplitude, rise, decay and width) for 30 min time point. C, Same as B for 24
hr time point. Non-toxic compounds are shown as blue circles. Cardiotoxic compounds are
shown in red (triangles – compounds with known dopamine- and/or histamine-ergic activity,
diamonds – compounds with known effects on ion channels, squares – other cardiotoxic
compounds).
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Relative cardiosafety ranking of Screen-Well™ Cardiotoxicity Library drugs. ToxPi scores
(see Supplemental Tables 5 and 6) were used to create a relative ranking of screened drugs
using multiparametric data collected from 30 min (A) and 24 hr (B) time points. Note that
cell viability data for 30 min time point was collected 24 hrs after addition of chemicals to
cells. Blue squares – non-toxic drugs, red squares – cardiotoxic drugs. Representative
ToxPi-es for two non-toxic and two cardiotoxic compounds are shown to visualize the
relative contribution of each parameter (represented in colors of each slice) to the overall
score of a compound.
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